Amneal Pharmaceuticals Executive and Leadership Team

Chirag Patel, the President & Co-Chief Executive Officer at Amneal Pharmaceuticals, directs the company's overarching strategy and operational execution. Patel guides Amneal's expansion across its diverse business segments, including U.S. generics, branded products, institutional injectables, and biosimilars, ensuring alignment with the mission to provide affordable access to essential medicines. This leadership role involves fostering innovation and driving growth in select international markets, leveraging the company's robust scientific rigor and production capabilities. Patel oversees the integration of strategic investments and the development of complex products, positioning Amneal as a dynamic, purpose-driven pharmaceutical entity. By championing employee well-being and leadership development, Chirag Patel cultivates a culture that accelerates the delivery of solutions for tomorrow's health challenges, directly impacting the company's ability to meet important medical needs and enhance market accessibility.

Chintu Patel, the Co-Chief Executive Officer at Amneal Pharmaceuticals, spearheads the company's strategic vision and global market positioning. Patel drives Amneal's evolution into a fully integrated pharmaceutical company, emphasizing the delivery of more affordable access to essential medicines worldwide. This executive leadership encompasses the expansion of branded business, institutional injectables, and biosimilars, alongside the foundational U.S. generics segment. Patel directs significant investments in world-class scientific rigor, advanced production capabilities, and commercial infrastructure, ensuring Amneal remains at the forefront of pharmaceutical innovation. By focusing on broadening portfolios in new categories and geographies, Chintu Patel accelerates the company's ability to address critical medical needs and deliver solutions for complex health challenges, reinforcing Amneal's commitment to making healthy possible and enhancing global healthcare outcomes.

Tasos Konidaris, the Chief Financial Officer at Amneal Pharmaceuticals, manages the company's financial strategy and fiscal operations. Konidaris oversees all aspects of financial planning, reporting, and capital allocation, ensuring robust fiscal health across Amneal's global operations. This role is critical in supporting the company's integrated business model, which spans U.S. generics, branded products, institutional injectables, and biosimilars. By guiding investment decisions, Tasos Konidaris enables strategic expansion into new categories and geographies, reinforcing Amneal's commitment to delivering affordable access to essential medicines. The Chief Financial Officer ensures financial discipline and optimizes resource utilization to support research and development, production capabilities, and commercial infrastructure. Konidaris's financial stewardship directly contributes to Amneal's ability to meet important medical needs and achieve sustainable growth in the dynamic pharmaceutical market.

Jd Schaub, the Executive Vice President & Chief Operating Officer at Amneal Pharmaceuticals, manages the company's day-to-day operational execution and supply chain management. Schaub oversees the seamless integration of Amneal's diverse business units, including U.S. generics, branded products, institutional injectables, and biosimilars, ensuring efficient production and delivery of essential medicines. This executive role is pivotal in optimizing manufacturing processes, enhancing production capabilities, and maintaining rigorous quality standards across all facilities. Jd Schaub drives operational excellence to support Amneal's mission of providing affordable access to critical pharmaceuticals globally. By focusing on efficiency and scalability, the Chief Operating Officer enables the company to meet increasing market demands and expand its reach into new geographies. Schaub's leadership ensures that Amneal's commercial infrastructure effectively supports innovation and the delivery of solutions for evolving healthcare needs.

Andy Caraballo, the President at Amneal Pharmaceuticals, leads specific strategic initiatives and operational areas within the organization. Caraballo's executive focus involves driving growth and operational efficiency in key segments of Amneal's business, contributing to the company's overall mission of delivering more affordable access to essential medicines. This leadership role supports the expansion of Amneal's diverse portfolio, which includes U.S. generics, branded products, institutional injectables, and biosimilars. By overseeing critical projects and fostering cross-functional collaboration, Andy Caraballo enhances Amneal's ability to innovate and meet important medical needs. The President's contributions are integral to strengthening the company's commercial infrastructure and ensuring the successful execution of strategic objectives, reinforcing Amneal's position as a dynamic pharmaceutical leader.

Laura Grant, the Senior Vice President, Chief Information Officer at Amneal Pharmaceuticals, directs the company's technology strategy and digital infrastructure. Grant oversees the implementation and management of IT systems that support Amneal's integrated global operations, including its U.S. generics, branded business, institutional injectables, and biosimilars segments. This leadership ensures that technology enhances operational efficiency, data security, and innovation across all departments. Grant's responsibilities include driving digital transformation initiatives that bolster Amneal's scientific rigor, production capabilities, and commercial reach. By optimizing information flow and leveraging advanced technological solutions, Laura Grant supports the company's mission to deliver more affordable access to essential medicines and address complex health challenges. The Chief Information Officer's strategic technology guidance is fundamental to Amneal's continued growth and market competitiveness.

Jatin Savani, the Sr. General Manager - Global Quality Management (Compliance, Supplier Quality, External Manufacturing and Chief Marketing Officer, SETE) at Amneal Pharmaceuticals, directs critical quality assurance and marketing functions. Savani oversees global compliance, supplier quality, and external manufacturing operations, ensuring adherence to the highest industry standards across Amneal's pharmaceutical portfolio, including generics, branded products, injectables, and biosimilars. This dual role also encompasses marketing strategy for the SETE division, driving market penetration and brand visibility. Jatin Savani's commitment to quality underpins the company's ability to deliver safe and effective medicines, reinforcing its purpose-driven approach. By managing supplier relationships and external manufacturing partnerships, Savani ensures the integrity of the supply chain, directly supporting Amneal's mission to make healthy possible and provide affordable access to essential treatments worldwide.

Jason Daly, the Executive Vice President & Chief Legal Officer at Amneal Pharmaceuticals, provides strategic legal counsel and oversees all legal affairs for the company. Daly manages corporate governance, regulatory compliance, intellectual property, and litigation, ensuring Amneal operates within legal frameworks across its global business, encompassing generics, branded products, injectables, and biosimilars. This executive leadership is crucial for navigating the complex regulatory landscape of the pharmaceutical industry and protecting the company's interests. Jason Daly's expertise supports Amneal's mission to deliver affordable access to essential medicines by mitigating legal risks and facilitating strategic partnerships. The Chief Legal Officer plays a vital role in safeguarding the company's reputation and ensuring ethical business practices, contributing directly to Amneal's sustained growth and its commitment to making healthy possible.